All In Biotech

Drug Trial Radar · NCT07011186

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Apr 17, 2024

Primary completion

Oct 2025

Study completion Oct 2026

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.

Conditions

  • Myeloid Malignancy

Interventions

  • TQB3909 Tablets + AzacitidineDrug

    TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AE) and serious adverse events (SAE), abnormal laboratory parametersTime frame: Up to 24 weeks
  2. Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) RateTime frame: Up to 4 weeks

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • Beijing Chaoyang Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Not yet recruiting

  • Harbin The First Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Zhuzhou Central Hospita

    Zhuzhou, Hunan, China · Not yet recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Tai'an Central Hospital (Tai'an Central Hospital affiliated to Qingdao University, Mount Taishan Medical Center)

    Taian, Shandong, China · Not yet recruiting

  • Zibo Central Hospital

    Zibo, Shandong, China · Not yet recruiting

  • ShangHai Tongren Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Pudong New Area People's Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • People's hospital of deyang city

    Deyang, Sichuan, China · Not yet recruiting

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • People's Hospital of Tianjin (City)

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.